A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
An expert from the trial tech firm explains how the 21st Century Cures Act and other recent regulatory advancements can elevate clinical data registries.
An expert from trial tech specialist Komodo Health talks about how real-world evidence use could elevate study design, conserve costs, and improve recruitment.
An expert from the CRO discusses the role real-world data plays in developing therapies, with benefits ranging from speeding recruitment to decreasing costs.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
Merck (known as MSD outside the US and Canada) will partner with the data insights firm on solutions that progress real-world research and innovations.
The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
A real-world evidence generation expert discusses how clinical trial teams can make use of RWE to help improve diversity and inclusivity in their studies.
Aetion and McKesson today announced a strategic collaboration to advance the use of real world evidence in cancer research – offering joint solutions to support the FDA’s demonstration project and commercial customers.
The Friends of Cancer Research, in collaboration with Iqvia and other health care research organizations, are working to determine where and when real-world data can be trusted.
Aetion today announced that former FDA Commissioner Scott Gottlieb has joined its board of directors to help to advance the use of RWE in drug development and commercialization.
Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.
The network for clinical and imaging data launches a new ‘Real World Imaging’ offering to complement existing real world evidence – and help overcome the challenges of bias and homogeneity, says CEO.
Iqvia leads the real world evidence market, which is at an inflection point, as pharma furthers its investment and vendors improve capabilities, according to a recent report.
PPD’s Evidera business unit is set to acquire Medimix International, a global technology company with a real-world evidence service offering that includes access to patient-level data, data analytics, and visualization capabilities.
Bristol-Myers Squibb enters a multi-year strategic agreement with Concerto HealthAI to use machine learning to aid in protocol design for precision treatment and improved patient outcomes.
Novartis Pharma AG partners with Target PharmaSolutions to support its global longitudinal observational study designed to generate real-world clinical data.
PPD’s agreement with China-based Happy Life Tech focuses on site selection, patient recruitment, and real-world evidence generation for customers globally.
Aetion aims to advance the adoption of and standards for real-world evidence backed by a strategic investment from several global biopharma and health care companies.
The owners of Synteract, Amulet Capital Partners, have acquired a global health communications and market access group with plans to merge it with Peloton Advantage, which it purchased earlier this year.
The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts.
The FDA recently released open source code and technical documents for its new mobile app – MyStudies – which is designed to collect information about medication use, health system touchpoints, and patient-reported outcomes.
Litmus Health’s profile of the wearables market names the top 15 devices today available to researchers incorporating real-life data into studies and trials – with a focus on data quality and transparency.
Parexel is adopting Medidata’s Shyft Analytics platform to bolster its real-world evidence generation and outcomes research offering to biopharmaceutical and medical device clients.
PRA Health Sciences is looking at and assessing various opportunities using real world data – as the company has become reliant on data as part of its clinical process, says CEO.
Hybrid study designs can be advantageous for the generation of real world evidence, providing a potential solution to the challenges presented by observational studies.
Cytel examines the gap between controlled experiment and real-world data at a time when the industry is collecting more data from more sources than ever before.
To improve clinical trial design, site selection, and patient enrollment, the real-world data solutions firm Clinerion is partnering with Patient iP, a health data and analytics company.